18. Spinocerebellar degeneration Clinical trials / Disease details
Clinical trials : 76 / Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04921930 (ClinicalTrials.gov) | July 1, 2021 | 31/5/2021 | Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) | Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) Phase I-II Efficacy-Toxicity of Artesunate in Friedreich Ataxia | Friedreich Ataxia | Drug: Artesunate Oral Product | Institut National de la Santé Et de la Recherche Médicale, France | Imagine Institute | Not yet recruiting | 16 Years | 65 Years | Male | 20 | Phase 1/Phase 2 | NULL |